Pavoda logo1
Pavoda twitter 20400x400 v3.1

Pavoda

Pavoda's novel SafelyFlush device and consumable reduce C. difficile and norovirus infections in hospitals and are used on existing industrial toilets.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Boxford, MA, USA
  • Currency USD
  • Founded April 2013
  • Employees 2
  • Website pavoda.com

Company Summary

C. difficile is the largest source of hospital-acquired infections in the U.S. It is also a challenging bacteria to treat due to its chemically resistant spores, which remain in the environment for months. Infected patients shed billions of spores in their stool, and toilet flushing aerosolizes the spores. Pavoda’s SafelyFlush© technology infuses a proprietary chemical during each flush, reduces aerosols and kills bacteria, spores, and viruses.

Team

  • Dr. Traverso is a fellow in the Division of Gastroenterology, Massachusetts General Hospital. He received his Ph.D. from the lab of Prof. Vogelstein at Johns Hopkins University and completed his internal medicine residency at the Brigham and Women’s Hospital, Harvard Medical School. His work focuses on colon cancer and currently on development of technologies for drug delivery through the gastrointestinal tract in the lab of Prof. Langer at MIT.

  • 856a2d00 cb6d 49ea 861d ed9fb8bda764
    Chief Scientific Officer

    Dr. Laken holds a B.S. in Genetics and Cell Biology from the University of Minnesota and a Ph.D. in Cellular and Molecular Medicine from the Johns Hopkins School of Medicine. Dr. Laken is a recipient of several awards, including the MIT Technology Review 100 Young Innovators Award (2002). He holds six patents and has developed four commercially available DNA-based diagnostic products, including while at Exact Sciences.

  • Photo
    President

    David Deems has over 25 years in life sciences and diagnostics with a focus on development and validation of novel technologies for new or emerging markets. David has developed and successfully launched novel products into the diagnostic and drug discovery markets, for both large and small companies, including Becton Dickinson, EXACT Sciences, Predicant Biosciences and, most recently, as CEO of Xceed Molecular, a molecular diagnostics company.

Advisors